Intracerebral hemorrhage
Conditions
Interventions
the experimental group:intravenous injection of deferoxamine mesylate (Desferal?)
the control group:standardized treatment
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
22 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age older than 22 years; 2) spontaneous ICH confirmed by CT; 3) onset within 18 hours; 4) signed informed consent; and 5) clinical status of stable condition.
Exclusion criteria
Exclusion criteria: 1) Allergic to deferoxamine mesylate and the like; 2) serum creatinine more than 2 mg/dL; 3) diagnosed with iron deficiency anemia, hemoglobin less than 7 g/L, or patients requiring transfusion therapy; 4) plans to implement surgical intervention; 5) tumor-related ICH patients, taking warfarin or those with coagulation disorders (INR more than 1.7), ruptured aneurysms, arteriovenous malformations, or venous thrombosis; 6) changes in the midline structure of the brain or patients with herniation; 7) deep coma (Glasgow Coma Scale (GCS) score less than 5 points); 8) taking iron supplements (more than 325 mg of iron) or prochlorperazine; 9) heart failure or need to take vitamin C more than 500 mg daily; 10) hearing impaired; 11) systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg patients, after three consecutive blood pressure measurements; 12) pregnant or lactating women; 13) alcoholism, drug dependence, poor compliance, or other factors that could affect research project completion; 14) the existence of any condition that could increase the patient's risk; 15) participation in another clinical trial at the same time; or 16) refused to accept cardiopulmonary resuscitation during hospitalization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| edem; | — |
Countries
China
Contacts
Public ContactXuguang Gao
Outcome results
None listed